# A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

> **NCT05966584** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Benralizumab
- **DRUG:** fulvestrant or AIs) and PI3K inhibition (alpelisib)

## Key facts

- **NCT ID:** NCT05966584
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-06
- **Primary completion:** 2024-08-02
- **Final completion:** 2024-08-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Limited amount of eligible participants
- **Last updated:** 2024-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966584, "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05966584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*